(Q37310683)

19 August 2017

1 reference

title

Role of ambrisentan in the management of pulmonary hypertension (English)

1 reference

19 August 2017

main subject

arterial hypertension

0 references

author name string

Sandra L Hrometz

series ordinal

1

1 reference

19 August 2017

Kelly M Shields

series ordinal

2

1 reference

19 August 2017

language of work or name

English

0 references

publication date

28 October 2008

1 reference

Annals of Pharmacotherapy

19 August 2017

published in

1 reference

19 August 2017

volume

42

1 reference

19 August 2017

issue

11

1 reference

19 August 2017

page(s)

1653-1659

1 reference

Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines

19 August 2017

cites work

1 reference

Diagnosis and differential assessment of pulmonary arterial hypertension

21 January 2018

1 reference

Cellular and molecular pathobiology of pulmonary arterial hypertension

21 January 2018

1 reference

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

Treatment of pulmonary arterial hypertension

21 January 2018

1 reference

Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels.

21 January 2018

1 reference

21 January 2018

Endothelin antagonists

1 reference

Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor

21 January 2018

1 reference

Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells

21 January 2018

1 reference

Ambrisentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology

21 January 2018

1 reference

Endothelin antagonism in pulmonary arterial hypertension

21 January 2018

1 reference

Vascular endothelin in hypertension

21 January 2018

1 reference

Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes

21 January 2018

1 reference

Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.

21 January 2018

1 reference

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

Clinical pharmacology of bosentan, a dual endothelin receptor antagonist

21 January 2018

1 reference

Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension

21 January 2018

1 reference

Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

21 January 2018

1 reference

Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology

21 January 2018

1 reference

Pulmonary Arterial Hypertension

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1L014

1 reference

release_wwmlxkoesjc77ixi4dpb4in4ly

19 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wwmlxkoesjc77ixi4dpb4in4ly

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference